Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Payables: 2010-2024

Historic Payables for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $3.3 million.

  • China Pharma Holdings' Payables rose 86.37% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 40.51%. This contributed to the annual value of $3.3 million for FY2024, which is 2.59% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Payables is $3.3 million, which was down 2.59% from $3.4 million recorded in FY2023.
  • China Pharma Holdings' Payables' 5-year high stood at $6.2 million during FY2022, with a 5-year trough of $2.7 million in FY2020.
  • Its 3-year average for Payables is $4.3 million, with a median of $3.4 million in 2023.
  • Per our database at Business Quant, China Pharma Holdings' Payables skyrocketed by 102.07% in 2022 and then tumbled by 44.81% in 2023.
  • Over the past 5 years, China Pharma Holdings' Payables (Yearly) stood at $2.7 million in 2020, then climbed by 11.47% to $3.1 million in 2021, then skyrocketed by 102.07% to $6.2 million in 2022, then crashed by 44.81% to $3.4 million in 2023, then dropped by 2.59% to $3.3 million in 2024.